Mustang Bio, Inc. (NasdaqCM: MBIO)
Health Care · Biotechnology · US
$0.38
-5.92% today · -76.0% 1Y
Mustang Bio, Inc. (NasdaqCM: MBIO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.85M and employs 4 people.
Over the last twelve months the share price has lost 76.0%, trading between 0.37 and 1.69.
Tweenvest scores Mustang Bio, Inc. across four factors: quality 36/100, value 13/100. Its strongest factor is quality.
MBIO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.85M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.46
- Dividend yield
- —
- Beta (5Y)
- 2.09
- 52-week high
- $1.69
- 52-week low
- $0.37
- Avg volume (3M)
- —
- Shares outstanding
- 7.58M
- Employees
- 4
- Next earnings
- —
About Mustang Bio, Inc.
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
- ISIN
- US62818Q3020
- Founded
- 2015
- Listed since
- Aug 22, 2017
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Restart Life Sciences Corp.CNSX: HEAL | $3.06M | CA$0.07 | -6.67% |
| GRI Bio, Inc.NasdaqCM: GRI | $3.02M | $1.38 | -20.69% |
| Eocene Ltd.NasdaqCM: EOCN | $2.97M | $2.85 | -19.49% |
| Aptevo Therapeutics Inc.NasdaqCM: APVO | $2.92M | $1.62 | -9.50% |
| BSF Enterprise PlcLSE: BSFA | $2.82M | £0.01 | +0.00% |
| HCW Biologics Inc.NasdaqCM: HCWB | $2.77M | $1.24 | -22.50% |
| Modus Therapeutics Holding AB (publ)OM: MODTX | $2.76M | Skr0.18 | -52.45% |
| Vaccinex, Inc.OTCPK: VCNX | $2.69M | $1.01 | -11.81% |
Figures last refreshed Oct 18, 2026.